glp 1 neurological effects GLP-1 for Weight Loss and Diabetes GLP-1 Receptor Agonists in Neurodegeneration:

Survodutide (Boehringer Ingelheim): Another Glucagon Approach Survodutide is a dual GLP-1 and glucagon agonist (it skips GIP)

Mao D, Cao H, Shi M, et al

Patients interested in retatrutide for any clinical reason would need to enrol in one of the active TRIUMPH Phase 3 trials through Eli Lilly's investigator network

Clinicians can use this as an opportunity to explain, in understandable terms, how GLP1s control appetite and cravings, and to guide patients toward long-term success through behavioral and nutritional support

Retatrutide Dosage and Cardiometabolic Biomarker Effects Beyond body weight reduction, the Phase 2 clinical data provide insight into how retatrutide dosage affects a range of cardiometabolic biomarkers

Data were collected July 8 - August 8, 2024 in Japan (n=4502), and September 5 - October 14, 2024 in China (n=4519)